Trevi Historical Financial Ratios

TRVI Stock

USD 2.88 0.04 1.37%

Trevi Therapeutics is promptly reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.19, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.0 will help investors to properly organize and evaluate Trevi Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

About Trevi Financial Ratios Analysis

Trevi TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Trevi Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Trevi financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Trevi Therapeutics history.

Trevi Therapeutics Financial Ratios Chart

As of now, Trevi Therapeutics' Payables Turnover is increasing as compared to previous years. The Trevi Therapeutics' current Current Ratio is estimated to increase to 15.78, while Free Cash Flow Yield is projected to decrease to (0.25).

Ev To Sales Inventory Turnover Net Income Per Share Days Of Inventory On Hand

Add Fundamental

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Trevi Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.As of now, Trevi Therapeutics' Payables Turnover is increasing as compared to previous years. The Trevi Therapeutics' current Current Ratio is estimated to increase to 15.78, while Free Cash Flow Yield is projected to decrease to (0.25).

	2023	2024 (projected)
Payables Turnover	0.068	0.0714
Days Of Inventory On Hand	8.0K	7.6K

Payables Turnover Days Of Inventory On Hand

Trevi Therapeutics fundamentals Correlations

	Dividend Yield	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow
Dividend Yield		-0.3	-0.14	-0.05	-0.4	0.43	-0.3	-0.4	-0.43	-0.14	-0.4	0.48	-0.84	0.17	-0.26	0.54	-0.8	0.26	-0.26	0.53	0.27	0.09	-0.27	-0.21	-0.51	-0.27
Ptb Ratio	-0.3		0.83	-0.42	-0.41	-0.09	1.0	-0.41	0.92	0.52	-0.51	-0.6	0.69	0.64	0.82	-0.74	0.31	-0.55	0.83	-0.95	-0.67	-0.87	0.88	0.9	0.83	0.88
Book Value Per Share	-0.14	0.83		-0.37	-0.61	-0.31	0.83	-0.61	0.84	0.39	-0.66	-0.5	0.47	0.93	0.81	-0.7	0.12	-0.25	0.81	-0.79	-0.52	-0.68	0.87	0.86	0.79	0.87
Free Cash Flow Yield	-0.05	-0.42	-0.37		0.43	0.1	-0.42	0.43	-0.31	-0.65	0.44	0.6	-0.05	-0.37	-0.72	0.25	0.06	0.3	-0.72	0.34	0.26	0.78	-0.68	-0.7	-0.27	-0.68
Operating Cash Flow Per Share	-0.4	-0.41	-0.61	0.43		-0.13	-0.41	1.0	-0.18	-0.05	0.98	-0.01	0.08	-0.73	-0.52	0.42	0.41	0.14	-0.52	0.31	0.26	0.56	-0.53	-0.55	-0.05	-0.53
Capex To Depreciation	0.43	-0.09	-0.31	0.1	-0.13		-0.09	-0.13	-0.34	-0.32	-0.13	0.49	-0.32	-0.32	-0.28	0.21	-0.43	-0.55	-0.28	0.25	0.07	0.0	-0.31	-0.24	-0.46	-0.31
Pb Ratio	-0.3	1.0	0.83	-0.42	-0.41	-0.09		-0.41	0.92	0.52	-0.51	-0.6	0.69	0.64	0.82	-0.74	0.31	-0.55	0.83	-0.95	-0.67	-0.87	0.88	0.9	0.83	0.88
Free Cash Flow Per Share	-0.4	-0.41	-0.61	0.43	1.0	-0.13	-0.41		-0.18	-0.04	0.98	-0.01	0.08	-0.73	-0.52	0.42	0.41	0.14	-0.52	0.31	0.26	0.56	-0.53	-0.55	-0.05	-0.53
Roic	-0.43	0.92	0.84	-0.31	-0.18	-0.34	0.92	-0.18		0.6	-0.27	-0.73	0.72	0.64	0.79	-0.7	0.44	-0.4	0.79	-0.91	-0.56	-0.7	0.85	0.85	0.98	0.85
Inventory Turnover	-0.14	0.52	0.39	-0.65	-0.05	-0.32	0.52	-0.04	0.6		-0.05	-0.91	0.26	0.28	0.76	-0.42	0.31	-0.34	0.76	-0.47	-0.02	-0.63	0.7	0.71	0.63	0.7
Net Income Per Share	-0.4	-0.51	-0.66	0.44	0.98	-0.13	-0.51	0.98	-0.27	-0.05		-0.01	0.02	-0.77	-0.53	0.38	0.41	0.13	-0.53	0.39	0.4	0.64	-0.57	-0.59	-0.13	-0.57
Days Of Inventory On Hand	0.48	-0.6	-0.5	0.6	-0.01	0.49	-0.6	-0.01	-0.73	-0.91	-0.01		-0.51	-0.31	-0.82	0.6	-0.48	0.36	-0.82	0.62	0.2	0.62	-0.78	-0.76	-0.78	-0.78
Payables Turnover	-0.84	0.69	0.47	-0.05	0.08	-0.32	0.69	0.08	0.72	0.26	0.02	-0.51		0.16	0.51	-0.76	0.83	-0.43	0.51	-0.87	-0.43	-0.44	0.56	0.52	0.72	0.56
Cash Per Share	0.17	0.64	0.93	-0.37	-0.73	-0.32	0.64	-0.73	0.64	0.28	-0.77	-0.31	0.16		0.67	-0.45	-0.17	0.03	0.67	-0.55	-0.46	-0.58	0.73	0.73	0.58	0.73
Pocfratio	-0.26	0.82	0.81	-0.72	-0.52	-0.28	0.82	-0.52	0.79	0.76	-0.53	-0.82	0.51	0.67		-0.79	0.27	-0.49	1.0	-0.8	-0.38	-0.88	0.99	0.98	0.76	0.99
Interest Coverage	0.54	-0.74	-0.7	0.25	0.42	0.21	-0.74	0.42	-0.7	-0.42	0.38	0.6	-0.76	-0.45	-0.79		-0.53	0.57	-0.79	0.83	0.24	0.6	-0.79	-0.74	-0.68	-0.79
Payout Ratio	-0.8	0.31	0.12	0.06	0.41	-0.43	0.31	0.41	0.44	0.31	0.41	-0.48	0.83	-0.17	0.27	-0.53		-0.25	0.27	-0.54	0.08	-0.09	0.28	0.21	0.52	0.28
Capex To Operating Cash Flow	0.26	-0.55	-0.25	0.3	0.14	-0.55	-0.55	0.14	-0.4	-0.34	0.13	0.36	-0.43	0.03	-0.49	0.57	-0.25		-0.49	0.5	0.14	0.54	-0.45	-0.47	-0.34	-0.45
Pfcf Ratio	-0.26	0.83	0.81	-0.72	-0.52	-0.28	0.83	-0.52	0.79	0.76	-0.53	-0.82	0.51	0.67	1.0	-0.79	0.27	-0.49		-0.8	-0.38	-0.88	0.99	0.98	0.76	0.99
Days Payables Outstanding	0.53	-0.95	-0.79	0.34	0.31	0.25	-0.95	0.31	-0.91	-0.47	0.39	0.62	-0.87	-0.55	-0.8	0.83	-0.54	0.5	-0.8		0.61	0.78	-0.86	-0.85	-0.85	-0.86
Income Quality	0.27	-0.67	-0.52	0.26	0.26	0.07	-0.67	0.26	-0.56	-0.02	0.4	0.2	-0.43	-0.46	-0.38	0.24	0.08	0.14	-0.38	0.61		0.59	-0.47	-0.52	-0.47	-0.47
Roe	0.09	-0.87	-0.68	0.78	0.56	0.0	-0.87	0.56	-0.7	-0.63	0.64	0.62	-0.44	-0.58	-0.88	0.6	-0.09	0.54	-0.88	0.78	0.59		-0.89	-0.93	-0.59	-0.89
Ev To Operating Cash Flow	-0.27	0.88	0.87	-0.68	-0.53	-0.31	0.88	-0.53	0.85	0.7	-0.57	-0.78	0.56	0.73	0.99	-0.79	0.28	-0.45	0.99	-0.86	-0.47	-0.89		0.99	0.8	1.0
Pe Ratio	-0.21	0.9	0.86	-0.7	-0.55	-0.24	0.9	-0.55	0.85	0.71	-0.59	-0.76	0.52	0.73	0.98	-0.74	0.21	-0.47	0.98	-0.85	-0.52	-0.93	0.99		0.79	0.99
Return On Tangible Assets	-0.51	0.83	0.79	-0.27	-0.05	-0.46	0.83	-0.05	0.98	0.63	-0.13	-0.78	0.72	0.58	0.76	-0.68	0.52	-0.34	0.76	-0.85	-0.47	-0.59	0.8	0.79		0.8
Ev To Free Cash Flow	-0.27	0.88	0.87	-0.68	-0.53	-0.31	0.88	-0.53	0.85	0.7	-0.57	-0.78	0.56	0.73	0.99	-0.79	0.28	-0.45	0.99	-0.86	-0.47	-0.89	1.0	0.99	0.8

Click cells to compare fundamentals

Trevi Therapeutics Account Relationship Matchups

Trevi Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	0.81	1.6	1.05	1.16	1.61	1.69
Book Value Per Share	4.65	1.51	0.75	1.66	0.83	1.19
Free Cash Flow Yield	(0.52)	(0.66)	(1.62)	(0.23)	(0.24)	(0.25)
Operating Cash Flow Per Share	(1.97)	(1.61)	(1.27)	(0.44)	(0.32)	(0.34)
Capex To Depreciation	6.87	0.23	0.68	3.7	1.11	1.06
Pb Ratio	0.81	1.6	1.05	1.16	1.61	1.69
Free Cash Flow Per Share	(1.97)	(1.61)	(1.27)	(0.44)	(0.32)	(0.34)
Roic	(0.99)	(0.49)	(0.79)	(1.03)	(0.26)	(0.43)
Net Income Per Share	(2.22)	(1.81)	(1.49)	(0.45)	(0.29)	(0.31)
Payables Turnover	0.0244	0.0233	0.0176	0.0151	0.068	0.0714
Cash Per Share	4.88	2.49	1.61	1.87	0.84	0.8
Pocfratio	(1.91)	(1.51)	(0.62)	(4.42)	(4.18)	(4.39)
Capex To Operating Cash Flow	(0.008638)	(3.9E-4)	(0.001103)	(0.005643)	(0.00432)	(0.004536)
Pfcf Ratio	(1.9)	(1.51)	(0.62)	(4.4)	(4.17)	(4.38)
Roe	(0.48)	(1.2)	(1.99)	(0.27)	(0.35)	(0.37)
Ev To Operating Cash Flow	0.56	(0.45)	0.15	(4.3)	(3.21)	(3.37)
Pe Ratio	(1.69)	(1.33)	(0.53)	(4.27)	(4.57)	(4.79)
Return On Tangible Assets	(0.43)	(0.7)	(0.88)	(0.24)	(0.33)	(0.34)
Ev To Free Cash Flow	0.56	(0.44)	0.15	(4.28)	(3.19)	(3.35)
Earnings Yield	(0.29)	(0.59)	(0.75)	(1.9)	(0.23)	(0.22)
Net Debt To E B I T D A	2.14	0.95	0.68	0.11	0.92	0.62
Current Ratio	11.45	8.33	2.98	9.15	15.03	15.78
Tangible Book Value Per Share	4.65	1.51	0.75	1.66	0.83	1.19
Graham Number	15.24	7.85	5.0	4.11	2.35	2.23
Shareholders Equity Per Share	4.65	1.51	0.75	1.66	0.83	1.19
Debt To Equity	0.001815	0.52	0.85	0.0852	0.003707	0.003522
Capex Per Share	0.0176	7.67E-4	0.001772	0.002464	0.001383	0.001314
Graham Net Net	1.65	4.52	1.43	0.68	0.77	1.12
Interest Debt Per Share	0.008436	0.8	0.69	0.15	0.007038	0.006686
Debt To Assets	0.00165	0.3	0.38	0.0744	0.003423	0.003252
Enterprise Value Over E B I T D A	0.49	(0.4)	0.13	(4.06)	(3.01)	(3.16)
Price Earnings Ratio	(1.69)	(1.33)	(0.53)	(4.27)	(4.57)	(4.79)
Price Book Value Ratio	0.81	1.6	1.05	1.16	1.61	1.69
Price Earnings To Growth Ratio	0.55	0.0722	0.0298	0.0612	0.13	0.088

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:

How To Invest In Trevi

Details

Is Trevi Stock a good investment?

Details

What is Trevi Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Return On Assets

(0.37)

Return On Equity

(0.60)

The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Trevi Historical Financial Ratios

About Trevi Financial Ratios Analysis

Trevi Therapeutics Financial Ratios Chart

Ev To Sales

Inventory Turnover

Trevi Therapeutics fundamentals Correlations

Trevi Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Trevi Therapeutics fundamentals Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Ev To Operating Cash Flow
Ev To Operating Cash Flow	+ 0.99	Pocfratio
Ev To Free Cash Flow	+ 0.99	Pocfratio

Days Payables Outstanding	- 0.95	Pb Ratio
Days Payables Outstanding	- 0.95	Ptb Ratio
Pe Ratio	- 0.93	Roe
Days Of Inventory On Hand	- 0.91	Inventory Turnover
Days Payables Outstanding	- 0.91	Roic
Ev To Free Cash Flow	- 0.89	Roe